The impact of administration of tranexamic acid in reducing the use of red blood cells and other blood products in cardiac surgery

BMC Anesthesiology

Volumn 6, Issue , 2006, Pages

  Vuylsteke, Alain ^a   Saravanan, Palanikumar ^a   Gerrard, Caroline ^a   Cafferty, Fay ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FRESH FROZEN PLASMA; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HEART VALVE REPLACEMENT; HEART VALVE SURGERY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; REOPERATION; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION;

EID: 33748864202     PISSN: 14712253     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-6-9     Document Type: Article

References (32)

1. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001:CD001886.
2. Laupacis A, Fergusson D: Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997, 85:1258-1267.
3. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, Buller HR: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999, 354:1940-1947.
4. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT: Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998, 133:442-447.
5. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M: Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996, 111:1037-1046.
6. Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EE, Murday AJ, Parker DJ, Treasure T: Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995, 59:664-667.
7. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999, 340:438-447.
8. Chelemer SB, Prato BS, Cox PMJ, O'Connor GT, Morton JR: Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002, 73:138-142.
9. Armellin G, Casella S, Guzzinati S, Pasini L, Marcassa A, Giron G: Tranexamic acid in aortic valve replacement. J Cardiothorac Vasc Anesth 2001, 15:331-335.
10. Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O: Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000, 120:520-527.
11. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O: Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg 1999, 68:2252-6; discussion 2256-7.
12. Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS: Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 2005, 94:271-278.
13. Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, Geissler HJ, Mehlhorn U: Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. Curr Med Res Opin 2004, 20:121-126.
14. Nuttall GA, Oliver WC, Ereth MH, Santrach PJ, Bryant SC, Orszulak TA, Schaff HV: Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 2000, 92:674-682.
15. Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354:353-365.
16. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM: A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006, 46:327-338.
17. Royston D, Chhatwani A: Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf 2006, 5:539-552.
18. Levy JH: Aprotinin versus tranexamic acid: the controversy continues. Transfusion 2006, 46:319-320.
19. Vlahakes GJ: The value of phase 4 clinical testing. N Engl J Med 2006, 354:413-415.
20. Sedrakyan A, Atkins D, Treasure T: The risk of aprotinin: a conflict of evidence. Lancet 2006, 367:1376-1377.
21. Borzak S, Ridker PM: Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med 1995, 123:873-877.
22. Egger M, Smith GD: Misleading meta-analysis. Bmj 1995, 311:753-754.
23. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL: The dose-response relationship of tranexamic acid. Anesthesiology 1995, 82:383-392.
24. Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver WCJ, Sarpal RS, Oyen LJ, Ereth MH: Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001, 92:1131-1136.
25. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J: Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002, 97:390-399.
26. Karski JM, Dowd NP, Joiner R, Carroll J, Peniston C, Bailey K, Glynn MF, Teasdale SJ, Cheng DC: The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C). J Cardiothorac Vasc Anesth 1998, 12:642-646.
27. Lambert W, Brisebois FJ, Wharton TJ, Carrier RC, Boyle D, Rowe BH: The effectiveness of low dose tranexamic acid in primary cardiac surgery. Can J Anaesth 1998, 45:571-574.
28. Ninis N, Phillips C, Bailey L, Pollock JI, Nadel S, Britto J, Maconochie I, Winrow A, Coen PG, Booy R, Levin M: The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. Bmj 2005, 330:1475.
29. Rochon PA, Gurwitz JH, Sykora K, Mamdani M, Streiner DL, Garfinkel S, Normand SL, Anderson GM: Reader's guide to critical appraisal of cohort studies: I. Role and design. Bmj 2005, 330:895-897.
30. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM: Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. Bmj 2005, 330:960-962.
31. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM: Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. Bmj 2005, 330:1021-1023.
32. Arora RC, Legare JF, Buth KJ, Sullivan JA, Hirsch GM: Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies. Ann Thorac Surg 2004, 78:1547-1554.